DOCSLIB.ORG

Ferric Citrate

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Novel aspects of anemia and iron management in renal patients with or without cardiorenal syndrome Renal Unit, King’s College Hospital, London, UK 2002 2012 Killini 2012 2008 2018 2000 2010 2004 Erythropoiesis Hepcidin system Activation of HIF under hypoxic P300conditions HIF-β HIF-2α HIF-PH HRE EPO gene Plasma HIF system Fe-Tf Erythropoietin Iron SCF, IL-1, IL-3, SCF, GM-CSF, IL-6, IL-11 IL-3 About 8 Days Pluripotent Burst-Forming Colony-Forming Proerythro- Erythro- Reticulocytes RBCs Stem Cell Unit-Erythroid Unit-Erythroid blasts blasts Cells (BFU-E) Cells (CFU-E) Outline of lecture • What‘s new in anemia management? • What‘s new in iron management? • What‘s new in patients with cardiorenal syndrome? Controversies Conference on Iron Management in CKD | March 27-30, 2014 | San Francisco, California, USA Is there anything new in relation to target haemoglobin? Hb correction with ESA therapy 15 14 13 12 11 10 Hb (g/dl) Hb 9 • Reduced transfusions • Improved QoL, esp. physical domain 8 • Improved physical capacity • Positive cardiac effects 7 6 Hb correction with ESA therapy 15 14 13 12 11 10 Hb (g/dl) Hb 9 • Reduced transfusions • ? Improved QoL / ↑exercise capacity 8 • Increased CVS events, stroke, VTE • Increased cancer-related deaths 7 6 Hb correction with ESA therapy 15 14 13 12 11 10 Hb (g/dl) Hb 9 8 7 6 Safety Concerns in the TREAT Study 10 Darbepoetin alfa 8.9§ 8 Placebo 7.5‡ 7.1 6 5.0† 4 Patients (%) Patients 2 2.6 2.0‡ 0.6 1.1 0 Stroke Venous Arterial Cancer-related thromboembolic thromboembolic mortality* event event †, p<0.001 versus placebo ‡, p=0.02 versus placebo §, p=0.04 versus placebo *Amongst patients with a history of malignancy at baseline Pfeffer MA et al. N Engl J Med 2009;361:2019–2032. EPO has non-erythropoietic actions High EPO levels • 2+ VSMC [Ca ]i VSMC proliferation • • RAS activation EC proliferation Platelet production • • ET-1 Angiogenesis Platelet activity • Thromboxane • E selectin ¯ Prostacyclin • P selectin • ADMA • vWF ¯ • PAI-1 ¯ NO Blood access stenosis Proliferative retinopathy Vascular remodeling Hypertension Thrombosis Tumor growth Vaziri ND & Zhou X. Nephrol Dial Transplant 2009; 24: 1082–1088. Erythropoietin concentration-time profiles EPO conc. (mU/mL) Three 40 U/kg SC doses/wk 1000 Two 60 U/kg SC doses/wk One 120 U/kg SC dose/wk 100 Erythropoiesis ]range 10 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Time (days) Besarab et al, J Am Soc Nephrol 1992. Hb predicts survival in observational studies HD patients If a patient is NOT on ESA therapy and has a high Hb, is there a need to venesect / lose circuits? Ofsthun et al, Kidney Int 2003; 63: 1908-1914. Hb predicts survival in observational studies ND-CKD patients Survival of CKD Patients by Hemoglobin Level 1.00 0.95 Hemoglobin >= 130 g/L 0.90 120-129 g/L 0.85 0.80 110-119 g/L Probability of Survival of Probability 0.75 Log-Rank Test: p =0.0001 < 100 g/L 100-109 g/L If a patient0.70 is NOT on ESA therapy and has 0a 3high6 9 12Hb,15 18 is21 there24 27 30 33a 36need to Months from Hg Result venesect? ABSOLUTELY NOT! Levin A. et al, Nephrol Dial Transplant 2006; 21: 370-377. What about the trigger haemoglobin to initiate ESA therapy? When to initiate Hb therapy? 15 10 Hb (g/dL) 5 Caveats? Stage Stage Stage CKD stages 1–2 • Hb < 11 g/dL plus3 symptoms4 5 • Individualisation120–60 59–30 29–15 < 15 Declining GFR (mL/min) NHANES 3 data. What about the future of anaemia management in CKD? Erythropoietin concentration-time profiles EPO conc. (mU/mL) Three 40 U/kg SC doses/wk 1000 Two 60 U/kg SC doses/wk One 120 U/kg SC dose/wk New strategy 100 Erythropoiesis ]range patient’s own EPO level 10 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Time (days) Besarab et al, J Am Soc Nephrol 1992. Evolution of CKD Anaemia Treatment Transfusions ESAs HIF�stabilisers� HIF stabilisers – prolyl hydroxylase inhibitors Regulation of erythropoietin Hypoxia-Inducible Factor? (HIF) Regulation of HIF activity Inhibition of HIF under Activation of HIF under normoxic conditions hypoxic conditions HIF-PH HIF-PH HIF-α HIF-α HIF-α Proteasome O2 O2 P300 OH OH OH OH HIF-β VHL HIF-α HIF-α HIF-α Proteasomal degradation HRE Gene eg EPO HIF stabilisers l HIF is degraded by a prolyl hydroxylase enzyme l Orally-active inhibitors of PH have been synthesised l These drugs cause HIF levels to increase l More HIF leads to more EPO HIF PHIs in development Company Molecule Drug name Phase of development FibroGen FG-4592 Roxadustat Phase 3 Astellas Astra Zeneca GSK GSK 1278863 Daprodustat Phase 3 Akebia AKB-6548 Vadadustat Phase 3 Mitsubishi Otsuka Vifor Fresenius Bayer BAY 85-3934 Molidustat Phase 2/3 Japan Tobacco Inc JTZ-951 Phase 1 J Am Soc Nephrol 2016 Apr;27(4):1225-33. Roxadustat increases haemoglobin levels Besarab et al. J Am Soc Nephrol 2016 Apr;27(4):1225-33. The Erythropoietic Response mediated by HIF Roxadustat lowers hepcidin levels EPO Roxadustat Provenzano et al. ASN 2012 Abstract Besarab et al. J Am Soc Nephrol 2016 Apr;27(4):1225-33. Outline of lecture • What‘s new in anemia management? • What‘s new in iron management? • What‘s new in patients with cardiorenal syndrome? Controversies Conference on Iron Management in CKD | March 27-30, 2014 | San Francisco, California, USA Iron supplementation Dietary iron Oral iron IV iron Better Hb response with IV iron compared to oral or no iron 14 *p<0.05, **p<0.005 vs IV iron 12 ESA + IV iron ** ESA + oral iron 10 * ESA + no iron Hb (g/dL) Hb * **** ** * **** * 8 6 0 4 8 12 16 Time (weeks) Macdougall et al, Kidney Int 1996. Meta-analysis showed intravenous iron to be more favourable vs oral iron therapy in patients with ND-CKD Haemoglobin (Hb) level or change from baseline Study WMD (random) Weight WMD (random) or sub-category 95% CI % 95% CI Stoves 2001 6.27 -0.52 (-1.33, 0.29) Aggarwal 2003 8.04 0.49 (-0.21, 1.19) Charytan 2005 16.12 0.25 (-0.19, 0.69) van Wyck 2005 25.45 0.30 (0.02, 0.58) Agarwal 2006 18.75 0.20 (-0.18, 0.58) Spinovitz 2006 25.37 0.60 (0.32, 0.88) Total (95% CI) 100.00 0.31 (0.09, 0.53) Test for heterogeneity: Chi2 = 8.42, df = 5 (P=0.13), 2 = 40.6% Test for overall effect: Z=2.79 (P=0.005) -1 -0.5 0 0.5 1 Favours oral Favours IV • Most studies had short duration of follow-up • More randomized trials are required Rozen-Zvi et al. Am J Kidney Dis 2008;52:897–906. Oral iron – anything new? Newer oral iron preparations • Ferric citrate • Ferric maltol • Liposomal (sucrosomial) iron • Heme iron polypeptide Controversies Conference on Iron Management in CKD | March 27-30, 2014 | San Francisco, California, USA Intestinal absorption of iron Ferrous sulphate Ferrous fumarate Ferric citrate Ferrous succinate Heme iron Ferric maltol Ferrous gluconate polypeptide Adapted from G. Barragán-Ibañez et al. Rev Med Hosp Gen Mex 2016;79:88-97. Ferric citrate as a phosphate-binder 8 6 4 Active Control Ferric Citrate 2 Mean Phosphorus, mg/dL 0 Baseline Week 12 Week 24 Week 36 Week 48 Week 52 Treatment Difference at Week 52 ANCOVA, p=0.8 Controversies Conference on Iron Management in CKD | March 27-30, 2014 | San Francisco, California, USA Effect of phosphate-binders on ferritin Mean Ferritin Active Control Ferric Citrate (ng/mL) (n=135) (n=252) Baseline (Day 0) 609 593 Week 12 649 751 Week 24 652 846 Week 36 631 862 Week 48 619 881 Week 52 624 898 Change from Baseline at Week 52 15 305 % Change from Baseline 2.5% 51.4% Least Squares Mean Difference at Week 52 285 P-value <0.0001 41 Effect of phosphate-binders on TSAT Mean TSAT Active Control Ferric Citrate (%) (n=135) (n=252) Baseline (Day 0) 31 31 Week 12 31 40 Week 24 31 40 Week 36 31 40 Week 48 29 41 Week 52 30 39 Change from Baseline at Week 52 -1 8 % Change from Baseline -3.2% 25.8% Least Squares Mean Difference at Week 52 9 P-value <0.0001 42 Effect of phosphate-binders on IV iron use Last 6 and 9 months with no IV iron in the study Active Control Ferric Citrate % Subjects % 43 Effect of phosphate-binders on ESA dose 12,000 10,000 8,000 6,000 4,000 2,000 0 1st Quarter 2nd Quarter 3rd Quarter 4th Quarter Ferric Citrate Mean ESA Units/Week Active Control Mean ESA Units/Week Controversies Conference on Iron Management in CKD | March 27-30, 2014 | San Francisco, California, USA What’s new with IV iron? Included 7 RCTs comparing higher-dose IV iron with lower-dose intravenous iron, oral iron, or no iron in patients treated with dialysis that had all-cause mortality, infection, cardiovascular events, or hospitalizations as outcomes Besarab et al, 2002 Single-center (US), open-label, randomized, prospective 6-month study in HD patients N = 42 IV iron dextran (25-150 mg/wk to maintain TSAT 20-30%) (n=19 -- 15 completed) R IV iron dextran 4-6 x 100 mg doses to increase TSAT >30% and thereafter to maintain TSAT at 30-50% (n=23 -- 17 completed) Primary outcome: EPO dose (40% lower) No differences in hospitalizations or infection rate were noted Each group had 1 admission for an infectious etiology (pneumonia in the control group, line-related sepsis in the study group) Coyne et al, 2007 (“DRIVE”) Open-label, randomized, controlled, multicenter trial (37 US centers) N = 134 1 g of ferric gluconate (Ferrlecit) administered in 8 consecutive 125-mg doses R No iron 6-weeks follow-up Better Hb response (p<0.03) 13 infection episodes in 10 patients occurred in the control arm, and 12 infection episodes occurred in 8 patients in the IV iron arm Lewis et al, 2015 Phase 3, sequential, randomized, open-label trial (60 sites in the US and Israel) N = 441 Ferric citrate 1 g (210 mg ferric iron) R Calcium acetate (667 mg) or sevelamer (800 mg) 52-weeks follow-up Primary outcome – phosphate level 12.5% of patients
Recommended publications
  • Suomen Lääketilasto 2019

    Suomen Lääketilasto 2019

    SUOMEN LÄÄKETILASTO S LT FINNISH STATISTICS ON MEDICINES FSM 2019 Keskeisiä lukuja lääkkeiden myynnistä ja lääkekorvauksista vuonna 2019 Milj. € Muutos vuodesta 2018, % Lääkkeiden kokonaismyynti 3 460 5,2 avohoidon reseptilääkkeiden myynti (verollisin vähittäismyyntihinnoin) 2 284 4,4 avohoidon itsehoitolääkkeiden myynti (verollisin vähittäismyyntihinnoin) 357 0,8 sairaalamyynti (tukkuohjehinnoin) 818 9,9 Lääkkeistä maksetut korvaukset 1 551 6,2 peruskorvaukset 316 3,0 erityiskorvaukset 1 029 5,2 lisäkorvaukset 205 17,7 Key figures for medicine sales and their reimburssement in 2019 € million Change from 2018, % Total sales of pharmaceuticals 3,460 5.2 prescription medicines in outpatient care (at pharmacy prices with VAT) 2,284 4.4 OTC medicines in outpatient care (at pharmacy prices with VAT) 357 0.8 sales to hospitals (at wholesale prices) 818 9.9 Reimbursement of medicine costs 1,551 6.2 Basic Refunds 316 3.0 Special Refunds 1,029 5.2 Additional Refunds 205 17.7 Lähde: Fimean lääkemyyntirekisteri, Kelan sairausvakuutuskorvausten tilastointitiedosto. Source: Finnish Medicines Agency, Drug Sales Register; Register of Statistical Information on National Health Insurance General Benefit Payments. SUOMEN LÄÄKETILASTO FINNISH STATISTICS ON MEDICINES 2019 Lääkealan turvallisuus- ja kehittämiskeskus Fimea ja Kansaneläkelaitos Finnish Medicines Agency Fimea and Social Insurance Institution Helsinki 2020 LÄÄKEALAN TURVALLISUUS- KANSANELÄKELAITOS JA KEHITTÄMISKESKUS FIMEA FINNISH MEDICINES AGENCY FIMEA SOCIAL INSURANCE INSTITUTION Lääketurvallisuus Analytiikka- ja tilastoryhmä Pharmacovigilance Section for Analytics and Statistics Mannerheimintie 166 Nordenskiöldinkatu 12 P.O. Box 55 P.O. Box 450 FI-00034 Fimea FI-00056 Kela Finland Finland [email protected] [email protected] Puh. 029 522 3341 Puh. 020 634 11 Tel. +358 29 522 3341 Tel.
  • Us Anti-Doping Agency

    Us Anti-Doping Agency

    2019U.S. ANTI-DOPING AGENCY WALLET CARDEXAMPLES OF PROHIBITED AND PERMITTED SUBSTANCES AND METHODS Effective Jan. 1 – Dec. 31, 2019 CATEGORIES OF SUBSTANCES PROHIBITED AT ALL TIMES (IN AND OUT-OF-COMPETITION) • Non-Approved Substances: investigational drugs and pharmaceuticals with no approval by a governmental regulatory health authority for human therapeutic use. • Anabolic Agents: androstenediol, androstenedione, bolasterone, boldenone, clenbuterol, danazol, desoxymethyltestosterone (madol), dehydrochlormethyltestosterone (DHCMT), Prasterone (dehydroepiandrosterone, DHEA , Intrarosa) and its prohormones, drostanolone, epitestosterone, methasterone, methyl-1-testosterone, methyltestosterone (Covaryx, EEMT, Est Estrogens-methyltest DS, Methitest), nandrolone, oxandrolone, prostanozol, Selective Androgen Receptor Modulators (enobosarm, (ostarine, MK-2866), andarine, LGD-4033, RAD-140). stanozolol, testosterone and its metabolites or isomers (Androgel), THG, tibolone, trenbolone, zeranol, zilpaterol, and similar substances. • Beta-2 Agonists: All selective and non-selective beta-2 agonists, including all optical isomers, are prohibited. Most inhaled beta-2 agonists are prohibited, including arformoterol (Brovana), fenoterol, higenamine (norcoclaurine, Tinospora crispa), indacaterol (Arcapta), levalbuterol (Xopenex), metaproternol (Alupent), orciprenaline, olodaterol (Striverdi), pirbuterol (Maxair), terbutaline (Brethaire), vilanterol (Breo). The only exceptions are albuterol, formoterol, and salmeterol by a metered-dose inhaler when used
  • Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011

    Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011

    CLASSIFICATION DECISIONS TAKEN BY THE HARMONIZED SYSTEM COMMITTEE FROM THE 47TH TO 60TH SESSIONS (2011 - 2018) WORLD CUSTOMS ORGANIZATION Rue du Marché 30 B-1210 Brussels Belgium November 2011 Copyright © 2011 World Customs Organization. All rights reserved. Requests and inquiries concerning translation, reproduction and adaptation rights should be addressed to [email protected]. D/2011/0448/25 The following list contains the classification decisions (other than those subject to a reservation) taken by the Harmonized System Committee ( 47th Session – March 2011) on specific products, together with their related Harmonized System code numbers and, in certain cases, the classification rationale. Advice Parties seeking to import or export merchandise covered by a decision are advised to verify the implementation of the decision by the importing or exporting country, as the case may be. HS codes Classification No Product description Classification considered rationale 1. Preparation, in the form of a powder, consisting of 92 % sugar, 6 % 2106.90 GRIs 1 and 6 black currant powder, anticaking agent, citric acid and black currant flavouring, put up for retail sale in 32-gram sachets, intended to be consumed as a beverage after mixing with hot water. 2. Vanutide cridificar (INN List 100). 3002.20 3. Certain INN products. Chapters 28, 29 (See “INN List 101” at the end of this publication.) and 30 4. Certain INN products. Chapters 13, 29 (See “INN List 102” at the end of this publication.) and 30 5. Certain INN products. Chapters 28, 29, (See “INN List 103” at the end of this publication.) 30, 35 and 39 6. Re-classification of INN products.
  • The Influence of Inflammation on Anemia in CKD Patients

    The Influence of Inflammation on Anemia in CKD Patients

    International Journal of Molecular Sciences Review The Influence of Inflammation on Anemia in CKD Patients Anna Gluba-Brzózka 1,* , Beata Franczyk 1, Robert Olszewski 2 and Jacek Rysz 1 1 Department of Nephrology, Hypertension and Family Medicine, Medical University of Lodz, 90-549 Lodz, Poland; [email protected] (B.F.); [email protected] (J.R.) 2 Department of Geriatrics, National Institute of Geriatrics Rheumatology and Rehabilitation and Department of Ultrasound, Institute of Fundamental Technological Research, Polish Academy of Sciences, Warsaw, Poland (IPPT PAN), 02-106 Warsaw, Poland; [email protected] * Correspondence: [email protected] Received: 18 November 2019; Accepted: 19 January 2020; Published: 22 January 2020 Abstract: Anemia is frequently observed in the course of chronic kidney disease (CKD) and it is associated with diminishing the quality of a patient’s life. It also enhances morbidity and mortality and hastens the CKD progression rate. Patients with CKD frequently suffer from a chronic inflammatory state which is related to a vast range of underlying factors. The results of studies have demonstrated that persistent inflammation may contribute to the variability in Hb levels and hyporesponsiveness to erythropoietin stimulating agents (ESA), which are frequently observed in CKD patients. The understanding of the impact of inflammatory cytokines on erythropoietin production and hepcidin synthesis will enable one to unravel the net of interactions of multiple factors involved in the pathogenesis of the anemia of chronic disease. It seems that anti-cytokine and anti-oxidative treatment strategies may be the future of pharmacological interventions aiming at the treatment of inflammation-associated hyporesponsiveness to ESA.
  • Ferric Maltol) Capsules, for Oral Use ------ADVERSE REACTIONS------Initial U.S

    Ferric Maltol) Capsules, for Oral Use ------ADVERSE REACTIONS------Initial U.S

    HIGHLIGHTS OF PRESCRIBING INFORMATION ------------------------WARNINGS AND PRECAUTIONS----------------------- These highlights do not include all the information needed to use • IBD flare: Avoid use in patients with IBD flare (5.1) ACCRUFERTM safely and effectively. See full prescribing • Iron overload: Accidental overdose of iron products is a leading information for ACCRUFER. cause of fatal poisoning in children under 6. Keep out of reach of children. (5.2) ACCRUFER (ferric maltol) capsules, for oral use --------------------------- ADVERSE REACTIONS------------------------------ Initial U.S. Approval: 2019 Most common adverse reactions (incidence > 1%) are flatulence, diarrhea, constipation, feces discolored, abdominal pain, nausea, -----------------------------INDICATIONS AND USAGE-------------------------- vomiting and abdominal discomfort/distension. (6.1) ACCRUFER is an iron replacement product indicated for the treatment of iron deficiency in adults. (1) To report SUSPECTED ADVERSE REACTIONS, contact [name of manufacturer] at [toll-free phone #] or FDA at 1-800-FDA-1088 or ------------------------DOSAGE AND ADMINISTRATION---------------------- www.fda.gov/medwatch. • 30 mg twice daily on an empty stomach (2.1) • Continue as long as necessary to replenish body iron stores (2.1) ------------------------------DRUG INTERACTIONS------------------------------- • Dimercaprol: Avoid concomitant use. (7.2) ---------------------DOSAGE FORMS AND STRENGTHS---------------------- • Oral Medications: Separate administration of ACCRUFER from Capsules:
  • Final Evidence Report

    Final Evidence Report

    Treatments for Anemia in Chronic Kidney Disease: Effectiveness and Value Final Evidence Report March 5, 2021 Prepared for ©Institute for Clinical and Economic Review, 2021 ICER Staff and Consultants University of Washington Modeling Group Reem A. Mustafa, MD, MPH, PhD Lisa Bloudek, PharmD, MS Associate Professor of Medicine Senior Research Scientist Director, Outcomes and Implementation Research University of Washington University of Kansas Medical Center Josh J. Carlson, PhD, MPH Grace Fox, PhD Associate Professor, Department of Pharmacy Research Lead University of Washington Institute for Clinical and Economic Review The role of the University of Washington is limited to Jonathan D. Campbell, PhD, MS the development of the cost-effectiveness model, and Senior Vice President for Health Economics the resulting ICER report does not necessarily Institute for Clinical and Economic Review represent the views of the University of Washington. Foluso Agboola, MBBS, MPH Vice President of Research Institute for Clinical and Economic Review Steven D. Pearson, MD, MSc President Institute for Clinical and Economic Review David M. Rind, MD, MSc Chief Medical Officer Institute for Clinical and Economic Review None of the above authors disclosed any conflicts of interest. DATE OF PUBLICATION: March 5, 2021 How to cite this document: Mustafa RA, Bloudek L, Fox G, Carlson JJ, Campbell JD, Agboola F, Pearson SD, Rind DM. Treatments for Anemia in Chronic Kidney Disease: Effectiveness and Value; Final Evidence Report. Institute for Clinical and Economic Review, March 5, 2021. https://icer.org/assessment/anemia-in-chronic-kidney-disease-2021/#timeline. Reem Mustafa served as the lead author for the report. Grace Fox led the systematic review and authorship of the comparative clinical effectiveness section in collaboration with Foluso Agboola and Noemi Fluetsch.
  • Ferric Maltol 30Mg Hard Capsules (Feraccru®) SMC No

    Ferric Maltol 30Mg Hard Capsules (Feraccru®) SMC No

    ferric maltol 30mg hard capsules (Feraccru®) SMC No. (1202/16) Shield TX UK Limited 04 November 2016 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in Scotland. The advice is summarised as follows: ADVICE: following a full submission ferric maltol (Feraccru®) is not recommended for use within NHS Scotland. Indication under review: in adults for the treatment of iron deficiency anaemia (IDA) in patients with inflammatory bowel disease (IBD). In a pooled analysis of two phase III studies in IBD patients with IDA who had failed previous treatment with oral ferrous products, there was a significantly greater increase in haemoglobin concentrations after 12 weeks of ferric maltol treatment compared with placebo. The submitting company did not present sufficiently robust clinical and economic analyses to gain acceptance by SMC. Overleaf is the detailed advice on this product. Chairman, Scottish Medicines Consortium Published 12 December 2016 1 Indication In adults for the treatment of iron deficiency anaemia (IDA) in patients with inflammatory bowel disease (IBD). Dosing Information One capsule twice daily, morning and evening, on an empty stomach. Treatment duration will depend on severity of iron deficiency but generally at least 12 weeks treatment is required. The treatment should be continued as long as necessary to replenish the body iron stores according to blood tests. Ferric maltol capsules should be taken whole on an empty stomach (with half a glass of water) as the absorption of iron is reduced when it is taken with food.
  • Analytical Approaches in Human Sports Drug Testing

    Analytical Approaches in Human Sports Drug Testing

    Received: 13 November 2018 Accepted: 18 November 2018 DOI: 10.1002/dta.2549 ANNUAL BANNED‐ SUBSTANCE REVIEW Annual banned‐substance review: Analytical approaches in human sports drug testing Mario Thevis1,2 | Tiia Kuuranne3 | Hans Geyer1,2 1 Center for Preventive Doping Research ‐ Institute of Biochemistry, German Sport Abstract University Cologne, Cologne, Germany A number of high profile revelations concerning anti‐doping rule violations over the 2 European Monitoring Center for Emerging past 12 months have outlined the importance of tackling prevailing challenges and Doping Agents, Cologne, Germany reducing the limitations of the current anti‐doping system. At this time, the necessity 3 Swiss Laboratory for Doping Analyses, University Center of Legal Medicine, Genève to enhance, expand, and improve analytical test methods in response to the sub- and Lausanne, Centre Hospitalier Universitaire stances outlined in the World Anti‐Doping Agency (WADA) Prohibited List represents Vaudois and University of Lausanne, Epalinges, Switzerland an increasingly crucial task for modern sports drug testing programs. The ability to Correspondence improve analytical testing methods often relies on the expedient application of novel Mario Thevis, Institute of Biochemistry ‐ Center for Preventive Doping Research, information regarding superior target analytes for sports drug testing assays, drug German Sport University Cologne, Am elimination profiles, and alternative sample matrices, together with recent advances Sportpark Müngersdorf 6, 50933 Cologne, Germany. in instrumental developments. This annual banned‐substance review evaluates litera- Email: thevis@dshs‐koeln.de ture published between October 2017 and September 2018 offering an in‐depth Funding information evaluation of developments in these arenas and their potential application to Federal Ministry of the Interior, Federal Republic of Germany; Manfred‐Donike‐Insti- substances reported in WADA's 2018 Prohibited List.
  • Roxadustat for the Treatment of Anemia in Patients with Chronic Kidney Diseases: a Meta-Analysis

    Roxadustat for the Treatment of Anemia in Patients with Chronic Kidney Diseases: a Meta-Analysis

    www.aging-us.com AGING 2021, Vol. 13, No. 13 Research Paper Roxadustat for the treatment of anemia in patients with chronic kidney diseases: a meta-analysis Li Zhang1, Jie Hou1, Jia Li1, Sen-Sen Su1, Shuai Xue2 1Department of Nephrology, The First Hospital of Jilin University, Jilin Province, China 2Department of Thyroid Surgery, The First Hospital of Jilin University, Jilin Province, China Correspondence to: Shuai Xue; email: [email protected] Keywords: roxadustat, chronic kidney disease, anemia, meta-analysis Received: January 22, 2021 Accepted: May 17, 2021 Published: June 11, 2021 Copyright: © 2021 Zhang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT Background: Anemia is a common complication of chronic kidney disease (CKD). Treating renal anemia with erythropoiesis-stimulating agents (ESAs) or erythropoietin analogs is effective but has side effects. Therefore, we performed a meta-analysis to assess the efficacy and safety of roxadustat in treating CKD-induced anemia. Methods: We searched publications online and conducted a meta-analysis and calculated relative risks with 95% confidence intervals (CIs) for dichotomous data and mean differences (MD) with 95% CIs for continuous data. Results: Of 110 articles, nine were included that contained 12 data sets and 11 randomized control trials on roxadustat. In the non-dialysis-dependent (NDD) high-dose/low-dose subgroups, the change in hemoglobin (Hb) levels was significantly higher in the roxadustat group than in the placebo group (P<0.0001, P=0.001, respectively).
  • Erythropoiesis and Chronic Kidney Disease–Related Anemia: from Physiology to New Therapeutic Advancements

    Erythropoiesis and Chronic Kidney Disease–Related Anemia: from Physiology to New Therapeutic Advancements

    Received: 21 April 2018 | Revised: 18 June 2018 | Accepted: 6 July 2018 DOI: 10.1002/med.21527 REVIEW ARTICLE Erythropoiesis and chronic kidney disease–related anemia: From physiology to new therapeutic advancements Valeria Cernaro1 | Giuseppe Coppolino2 | Luca Visconti1 | Laura Rivoli3 | Antonio Lacquaniti1 | Domenico Santoro1 | Antoine Buemi4 | Saverio Loddo5 | Michele Buemi1 1Chair of Nephrology, Department of Clinical and Experimental Medicine, University of Abstract Messina, Messina, Italy Erythropoiesis is triggered by hypoxia and is strictly 2Nephrology and Dialysis Unit, Department of regulated by hormones, growth factors, cytokines, and Internal Medicine, “Pugliese‐Ciaccio” Hospital of Catanzaro, Catanzaro, Italy vitamins to ensure an adequate oxygen delivery to all 3Unit of Nephrology, Department of Internal body cells. Abnormalities in one or more of these factors Medicine, Chivasso Hospital, Turin, Italy may induce different kinds of anemia requiring different 4Surgery and Abdominal Transplantation Division, Cliniques Universitaires Saint‐Luc, treatments. A key player in red blood cell production is Université Catholique De Louvain, Brussels, erythropoietin. It is a glycoprotein hormone, mainly Belgium 5Department of Clinical and Experimental produced by the kidneys, that promotes erythroid Medicine, University of Messina, Messina, progenitor cell survival and differentiation in the bone Italy marrow and regulates iron metabolism. A deficit in Correspondence erythropoietin synthesis is the main cause of the normo- Valeria Cernaro, Chair of Nephrology, Department of Clinical and Experimental chromic normocytic anemia frequently observed in pa- Medicine, University of Messina, Via tients with progressive chronic kidney disease. The Consolare Valeria n. 1, Messina 98124, Italy. Email: [email protected] present review summarizes the most recent findings about each step of the erythropoietic process, going from the renal oxygen sensing system to the cascade of events induced by erythropoietin through its own receptor in the bone marrow.
  • As Ferric Maltol)

    As Ferric Maltol)

    ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Feraccru 30 mg hard capsules 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains 30 mg iron (as ferric maltol). Excipient(s) with known effect Each capsule contains 91.5 mg of lactose monohydrate, 0.3 mg of Allura Red AC (E129) and 0.1 mg Sunset Yellow FCF (E 110). For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Hard capsule. Red capsule (19 mm long x 7 mm diameter) printed “30”. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Feraccru is indicated in adults for the treatment of iron deficiency. 4.2 Posology and method of administration Posology The recommended dose is one capsule twice daily, morning and evening, on an empty stomach (see section 4.5). Treatment duration will depend on the severity of iron deficiency, but generally at least 12-weeks treatment is required. It is recommended the treatment is continued as long as necessary to replenish the body iron stores according to blood tests. The elderly and patients with hepatic or renal impairment No dose adjustment is needed in elderly patients or patients with renal impairment (eGFR ≥15 ml/min/1.73 m2). No clinical data on the need to adjust the dose in patients with impaired hepatic function and/or renal impairment (eGFR <15 ml/min/1.73 m2) are available (see section 4.4). Paediatric population The safety and efficacy of Feraccru in children (17 years and under) has not yet been established. No data are available Method of administration Oral use.
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1

    Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1

    US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .